Cancer Center Support Grant
Cancer Center Support Grant
批准号:
7934388
负责人:
Riccardo Dalla-Favera
金额:
$26.7万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2011-09-29
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The Herbert Irving Comprehensive Cancer Center (HICCC) was designated an NCI Cancer Center in 1972 and gained comprehensive status in 1979. The HICCC is a component of Columbia University Medical Center and associated with New York-Presbyterian Hospital (NYPH). During the period 2003-07, CUMC and NYPH have committed over $312.7 million for i) new research initiatives in basic, clinical and population science; ii) new and expanded facilities for laboratory research and clinical activities; iii) recruitment and program restructuring; iv) support of the Center's administrative office; and v) bridge funding to offset reduced NCI CCSG support.
A new Director, Riccardo Dalla-Favera, MD, was appointed in 2005 and given: i) authority over new facilities, including the Irving Cancer Research Center (ICRC), a new 10-story building dedicated to cancer research, with state-of-the-art laboratories (100,000 square feet) and incremental clinical (30,000 square feet) space in the Herbert Irving Pavilion (HIP); ii) a broad-based recruitment plan, which has already attracted 8 new faculty members to the HICCC; and iii) restructuring and expansion of the shared resources. The Director has fully reshaped the senior leadership of the HICCC with appointments of a Deputy Director for Clinical Research and Associate Directors for Basic Research, Clinical Research, Population Science, Biomedical Informatics, Shared Resources and Administration. The programmatic structure of the HICCC has been reorganized to increase cancer focus and interdisciplinary collaboration, and now includes 216 members from 22 Departments and 6 Schools, assigned to two Basic Research programs (Cancer Signaling Networks and Cancer Genetics & Epigenetics), three Disease-Specific programs (Breast Cancer, Prostate Cancer, and Lymphoid Development & Malignancy), and two Population Science programs (Cancer Epidemiology and Prevention, Control & Disparities). The HICCC administers and supports a total of 12 Shared Resources, of which four have been recently created.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma
-
批准号:10737214
-
项目类别:
-
资助金额:$98.7万
-
财政年份:2023
-
负责人:Riccardo Dalla-Favera
-
依托单位:
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
-
批准号:10453790
-
项目类别:
-
资助金额:$94.08万
-
财政年份:2016
-
负责人:Riccardo Dalla-Favera
-
依托单位:
MSK SPORE in Lymphoma
-
批准号:9753960
-
项目类别:
-
资助金额:$209.4万
-
财政年份:2016
-
负责人:Riccardo Dalla-Favera
-
依托单位:
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
-
批准号:9528531
-
项目类别:
-
资助金额:$96.0万
-
财政年份:2016
-
负责人:Riccardo Dalla-Favera
-
依托单位:
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
-
批准号:9186876
-
项目类别:
-
资助金额:$40.6万
-
财政年份:2016
-
负责人:Riccardo Dalla-Favera
-
依托单位:
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
-
批准号:9977975
-
项目类别:
-
资助金额:$96.0万
-
财政年份:2016
-
负责人:Riccardo Dalla-Favera
-
依托单位:
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
-
批准号:10224858
-
项目类别:
-
资助金额:$96.0万
-
财政年份:2016
-
负责人:Riccardo Dalla-Favera
-
依托单位:
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
-
批准号:9326271
-
项目类别:
-
资助金额:$96.0万
-
财政年份:2016
-
负责人:Riccardo Dalla-Favera
-
依托单位:
Role of MEF2B mutations in lymphomagenesis
-
批准号:8697703
-
项目类别:
-
资助金额:$44.36万
-
财政年份:2014
-
负责人:Riccardo Dalla-Favera
-
依托单位:
Role of MEF2B mutations in lymphomagenesis
-
批准号:8849397
-
项目类别:
-
资助金额:$44.36万
-
财政年份:2014
-
负责人:Riccardo Dalla-Favera
-
依托单位:
The Role of NOTCH1 in the Pathogenesis of CLL.
-
批准号:8539207
-
项目类别:
-
资助金额:$35.83万
-
财政年份:2013
-
负责人:Riccardo Dalla-Favera
-
依托单位:
The Role of NOTCH1 in the Pathogenesis of CLL.
-
批准号:8643783
-
项目类别:
-
资助金额:$34.76万
-
财政年份:2013
-
负责人:Riccardo Dalla-Favera
-
依托单位:
The Role of NOTCH1 in the Pathogenesis of CLL.
-
批准号:8826085
-
项目类别:
-
资助金额:$35.83万
-
财政年份:2013
-
负责人:Riccardo Dalla-Favera
-
依托单位:
Role of acetyltransferase gene inactivation in follicular lymphoma pathogenesis
-
批准号:8446960
-
项目类别:
-
资助金额:$31.21万
-
财政年份:2012
-
负责人:Riccardo Dalla-Favera
-
依托单位:
Role of acetyltransferase gene inactivation in follicular lymphoma pathogenesis
-
批准号:8627966
-
项目类别:
-
资助金额:$32.2万
-
财政年份:2012
-
负责人:Riccardo Dalla-Favera
-
依托单位:
Role of acetyltransferase gene inactivation in follicular lymphoma pathogenesis
-
批准号:8222362
-
项目类别:
-
资助金额:$33.2万
-
财政年份:2012
-
负责人:Riccardo Dalla-Favera
-
依托单位:
Cancer Center Support Grant
-
批准号:7934425
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2009
-
负责人:Riccardo Dalla-Favera
-
依托单位:
PROGRAM PLANNING AND EVALUATION
-
批准号:7669890
-
项目类别:
-
资助金额:$1.45万
-
财政年份:2008
-
负责人:Riccardo Dalla-Favera
-
依托单位:
PROGRAM LEADERS
-
批准号:7669884
-
项目类别:
-
资助金额:$17.48万
-
财政年份:2008
-
负责人:Riccardo Dalla-Favera
-
依托单位:
DEVELOPMENTAL FUNDS
-
批准号:7669891
-
项目类别:
-
资助金额:$21.98万
-
财政年份:2008
-
负责人:Riccardo Dalla-Favera
-
依托单位:
国内基金
海外基金
登录
查看更多内容
金刚石NV center与磁子晶体强耦合的混合量子系统研究
-
批准号:12375018
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2023
-
负责人:李蓬勃
-
依托单位:
金刚石SiV center与声子晶体强耦合的新型量子体系研究
-
批准号:92065105
-
项目类别:重大研究计划
-
资助金额:80.0万元
-
批准年份:2020
-
负责人:李蓬勃
-
依托单位:
金刚石NV center与磁介质超晶格表面声子极化激元强耦合的新型量子器件研究
-
批准号:11774285
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2017
-
负责人:李蓬勃
-
依托单位:
室温下金刚石晶体内N-V center单电子自旋量子比特研究
-
批准号:10974251
-
项目类别:面上项目
-
资助金额:40.0万元
-
批准年份:2009
-
负责人:潘新宇
-
依托单位: